Recombinant Human Coagulation VIIa Market 2022: Industry Size, Emerging Trends, Growth Insights, Opportunities, and Forecast By 2028
Exclusive deal : 20% Instant discount on Direct purchases! Don't wait—claim your discount today!
Recombinant activated factor VII (rFVIIa) binds to exposed tissue factor at the place of tissue and vascular injury. Thrombin generated by this process activates platelets and the coagulation cascade.
This report aims to provide a comprehensive presentation of the global market for Recombinant Human Coagulation VIIa study by Market Intellix gives insights concerning the market elements influencing the market, Market scope, Market division, and overlays shadow upon the leading market players featuring the positive cutthroat scene and patterns beating the years.
Global Recombinant Human Coagulation VIIa Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Recombinant Human Coagulation VIIa Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Recombinant Human Coagulation VIIa companies in 2021 (%)
The global Recombinant Human Coagulation VIIa market was valued at 1166.6 million in 2021 and is projected to reach US$ 1488.4 million by 2028, at a CAGR of 3.5% during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Prefilled Syringe Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Recombinant Human Coagulation VIIa include Novo Nordisk, LFB SA HEMA Biologics, AryoGen Pharmed and GENERIUM, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
The study provides the Recombinant Human Coagulation VIIa manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Segmental Outline:
Global Recombinant Human Coagulation VIIa Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Recombinant Human Coagulation VIIa Market Segment Percentages, by Type, 2021 (%)
Prefilled Syringe
Vial
Global Recombinant Human Coagulation VIIa Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Recombinant Human Coagulation VIIa Market Segment Percentages, by Application, 2021 (%)
Congenital Hemophilia
Acquired Hemophilia
Others
Global Recombinant Human Coagulation VIIa Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Recombinant Human Coagulation VIIa Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Recombinant Human Coagulation VIIa revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Recombinant Human Coagulation VIIa revenues share in global market, 2021 (%)
Key companies Recombinant Human Coagulation VIIa sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Recombinant Human Coagulation VIIa sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Novo Nordisk
LFB SA HEMA Biologics
AryoGen Pharmed
GENERIUM
This Report Addresses:
– Market Intelligence enables effective decision-making
– Market estimates and forecasts from 2022 to 2028
– Growth opportunities and trend analysis
– Segment and regional revenue forecast for market evaluation
– Competitive strategy and analysis of market segments
– List of product innovations to stay on top.
– The impact of COVID-19 and how to survive in these fast-growing markets.
1 Introduction to Research & Analysis Reports
1.1 Recombinant Human Coagulation VIIa Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Recombinant Human Coagulation VIIa Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Recombinant Human Coagulation VIIa Overall Market Size
2.1 Global Recombinant Human Coagulation VIIa Market Size: 2021 VS 2028
2.2 Global Recombinant Human Coagulation VIIa Revenue, Prospects & Forecasts: 2017-2028
2.3 Global Recombinant Human Coagulation VIIa Sales: 2017-2028
3 Company Landscape
3.1 Top Recombinant Human Coagulation VIIa Players in Global Market
3.2 Top Global Recombinant Human Coagulation VIIa Companies Ranked by Revenue
3.3 Global Recombinant Human Coagulation VIIa Revenue by Companies
3.4 Global Recombinant Human Coagulation VIIa Sales by Companies
3.5 Global Recombinant Human Coagulation VIIa Price by Manufacturer (2017-2022)
3.6 Top 3 and Top 5 Recombinant Human Coagulation VIIa Companies in Global Market, by Revenue in 2021
3.7 Global Manufacturers Recombinant Human Coagulation VIIa Product Type
3.8 Tier 1, Tier 2 and Tier 3 Recombinant Human Coagulation VIIa Players in Global Market
3.8.1 List of Global Tier 1 Recombinant Human Coagulation VIIa Companies
3.8.2 List of Global Tier 2 and Tier 3 Recombinant Human Coagulation VIIa Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Recombinant Human Coagulation VIIa Market Size Markets, 2021 & 2028
4.1.2 Prefilled Syringe
4.1.3 Vial
4.2 By Type - Global Recombinant Human Coagulation VIIa Revenue & Forecasts
4.2.1 By Type - Global Recombinant Human Coagulation VIIa Revenue, 2017-2022
4.2.2 By Type - Global Recombinant Human Coagulation VIIa Revenue, 2023-2028
4.2.3 By Type - Global Recombinant Human Coagulation VIIa Revenue Market Share, 2017-2028
4.3 By Type - Global Recombinant Human Coagulation VIIa Sales & Forecasts
4.3.1 By Type - Global Recombinant Human Coagulation VIIa Sales, 2017-2022
4.3.2 By Type - Global Recombinant Human Coagulation VIIa Sales, 2023-2028
4.3.3 By Type - Global Recombinant Human Coagulation VIIa Sales Market Share, 2017-2028
4.4 By Type - Global Recombinant Human Coagulation VIIa Price (Manufacturers Selling Prices), 2017-2028
5 Sights By Application
5.1 Overview
5.1.1 By Application - Global Recombinant Human Coagulation VIIa Market Size, 2021 & 2028
5.1.2 Congenital Hemophilia
5.1.3 Acquired Hemophilia
5.1.4 Others
5.2 By Application - Global Recombinant Human Coagulation VIIa Revenue & Forecasts
5.2.1 By Application - Global Recombinant Human Coagulation VIIa Revenue, 2017-2022
5.2.2 By Application - Global Recombinant Human Coagulation VIIa Revenue, 2023-2028
5.2.3 By Application - Global Recombinant Human Coagulation VIIa Revenue Market Share, 2017-2028
5.3 By Application - Global Recombinant Human Coagulation VIIa Sales & Forecasts
5.3.1 By Application - Global Recombinant Human Coagulation VIIa Sales, 2017-2022
5.3.2 By Application - Global Recombinant Human Coagulation VIIa Sales, 2023-2028
5.3.3 By Application - Global Recombinant Human Coagulation VIIa Sales Market Share, 2017-2028
5.4 By Application - Global Recombinant Human Coagulation VIIa Price (Manufacturers Selling Prices), 2017-2028
6 Sights by Region
6.1 By Region - Global Recombinant Human Coagulation VIIa Market Size, 2021 & 2028
6.2 By Region - Global Recombinant Human Coagulation VIIa Revenue & Forecasts
6.2.1 By Region - Global Recombinant Human Coagulation VIIa Revenue, 2017-2022
6.2.2 By Region - Global Recombinant Human Coagulation VIIa Revenue, 2023-2028
6.2.3 By Region - Global Recombinant Human Coagulation VIIa Revenue Market Share, 2017-2028
6.3 By Region - Global Recombinant Human Coagulation VIIa Sales & Forecasts
6.3.1 By Region - Global Recombinant Human Coagulation VIIa Sales, 2017-2022
6.3.2 By Region - Global Recombinant Human Coagulation VIIa Sales, 2023-2028
6.3.3 By Region - Global Recombinant Human Coagulation VIIa Sales Market Share, 2017-2028
6.4 North America
6.4.1 By Country - North America Recombinant Human Coagulation VIIa Revenue, 2017-2028
6.4.2 By Country - North America Recombinant Human Coagulation VIIa Sales, 2017-2028
6.4.3 US Recombinant Human Coagulation VIIa Market Size, 2017-2028
6.4.4 Canada Recombinant Human Coagulation VIIa Market Size, 2017-2028
6.4.5 Mexico Recombinant Human Coagulation VIIa Market Size, 2017-2028
6.5 Europe
6.5.1 By Country - Europe Recombinant Human Coagulation VIIa Revenue, 2017-2028
6.5.2 By Country - Europe Recombinant Human Coagulation VIIa Sales, 2017-2028
6.5.3 Germany Recombinant Human Coagulation VIIa Market Size, 2017-2028
6.5.4 France Recombinant Human Coagulation VIIa Market Size, 2017-2028
6.5.5 U.K. Recombinant Human Coagulation VIIa Market Size, 2017-2028
6.5.6 Italy Recombinant Human Coagulation VIIa Market Size, 2017-2028
6.5.7 Russia Recombinant Human Coagulation VIIa Market Size, 2017-2028
6.5.8 Nordic Countries Recombinant Human Coagulation VIIa Market Size, 2017-2028
6.5.9 Benelux Recombinant Human Coagulation VIIa Market Size, 2017-2028
6.6 Asia
6.6.1 By Region - Asia Recombinant Human Coagulation VIIa Revenue, 2017-2028
6.6.2 By Region - Asia Recombinant Human Coagulation VIIa Sales, 2017-2028
6.6.3 China Recombinant Human Coagulation VIIa Market Size, 2017-2028
6.6.4 Japan Recombinant Human Coagulation VIIa Market Size, 2017-2028
6.6.5 South Korea Recombinant Human Coagulation VIIa Market Size, 2017-2028
6.6.6 Southeast Asia Recombinant Human Coagulation VIIa Market Size, 2017-2028
6.6.7 India Recombinant Human Coagulation VIIa Market Size, 2017-2028
6.7 South America
6.7.1 By Country - South America Recombinant Human Coagulation VIIa Revenue, 2017-2028
6.7.2 By Country - South America Recombinant Human Coagulation VIIa Sales, 2017-2028
6.7.3 Brazil Recombinant Human Coagulation VIIa Market Size, 2017-2028
6.7.4 Argentina Recombinant Human Coagulation VIIa Market Size, 2017-2028
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Recombinant Human Coagulation VIIa Revenue, 2017-2028
6.8.2 By Country - Middle East & Africa Recombinant Human Coagulation VIIa Sales, 2017-2028
6.8.3 Turkey Recombinant Human Coagulation VIIa Market Size, 2017-2028
6.8.4 Israel Recombinant Human Coagulation VIIa Market Size, 2017-2028
6.8.5 Saudi Arabia Recombinant Human Coagulation VIIa Market Size, 2017-2028
6.8.6 UAE Recombinant Human Coagulation VIIa Market Size, 2017-2028
7 Manufacturers & Brands Profiles
7.1 Novo Nordisk
7.1.1 Novo Nordisk Corporate Summary
7.1.2 Novo Nordisk Business Overview
7.1.3 Novo Nordisk Recombinant Human Coagulation VIIa Major Product Offerings
7.1.4 Novo Nordisk Recombinant Human Coagulation VIIa Sales and Revenue in Global (2017-2022)
7.1.5 Novo Nordisk Key News
7.2 LFB SA HEMA Biologics
7.2.1 LFB SA HEMA Biologics Corporate Summary
7.2.2 LFB SA HEMA Biologics Business Overview
7.2.3 LFB SA HEMA Biologics Recombinant Human Coagulation VIIa Major Product Offerings
7.2.4 LFB SA HEMA Biologics Recombinant Human Coagulation VIIa Sales and Revenue in Global (2017-2022)
7.2.5 LFB SA HEMA Biologics Key News
7.3 AryoGen Pharmed
7.3.1 AryoGen Pharmed Corporate Summary
7.3.2 AryoGen Pharmed Business Overview
7.3.3 AryoGen Pharmed Recombinant Human Coagulation VIIa Major Product Offerings
7.3.4 AryoGen Pharmed Recombinant Human Coagulation VIIa Sales and Revenue in Global (2017-2022)
7.3.5 AryoGen Pharmed Key News
7.4 GENERIUM
7.4.1 GENERIUM Corporate Summary
7.4.2 GENERIUM Business Overview
7.4.3 GENERIUM Recombinant Human Coagulation VIIa Major Product Offerings
7.4.4 GENERIUM Recombinant Human Coagulation VIIa Sales and Revenue in Global (2017-2022)
7.4.5 GENERIUM Key News
8 Global Recombinant Human Coagulation VIIa Production Capacity, Analysis
8.1 Global Recombinant Human Coagulation VIIa Production Capacity, 2017-2028
8.2 Recombinant Human Coagulation VIIa Production Capacity of Key Manufacturers in Global Market
8.3 Global Recombinant Human Coagulation VIIa Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Recombinant Human Coagulation VIIa Supply Chain Analysis
10.1 Recombinant Human Coagulation VIIa Industry Value Chain
10.2 Recombinant Human Coagulation VIIa Upstream Market
10.3 Recombinant Human Coagulation VIIa Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Recombinant Human Coagulation VIIa Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
Research Methodology:
Recombinant Human Coagulation VIIa Market Size Estimation
To estimate market size and trends, we use a combination of top-down and bottom-up methods. This allows us to evaluate the market from various perspectives—by company, region, product type, and end users.
Our estimates are based on actual sales data, excluding any discounts. Segment breakdowns and market shares are calculated using weighted averages based on usage rates and average prices. Regional insights are determined by how widely a product or service is adopted in each area.
Key companies are identified through secondary sources like industry reports and company filings. We then verify revenue estimates and other key data points through primary research, including interviews with industry experts, company executives, and decision-makers.
We take into account all relevant factors that could influence the market and validate our findings with real-world input. Our final insights combine both qualitative and quantitative data to provide a well-rounded view. Please note, these estimates do not account for unexpected changes such as inflation, economic downturns, or policy shifts.
Data Source
Secondary Sources
This study draws on a wide range of secondary sources, including press releases, annual reports, non-profit organizations, industry associations, government agencies, and customs data. We also referred to reputable databases and directories such as Bloomberg, Wind Info, Hoovers, Factiva, Trading Economics, Statista, and others. Additional references include investor presentations, company filings (e.g., SEC), economic data, and documents from regulatory and industry bodies.
These sources were used to gather technical and market-focused insights, identify key players, analyze market segmentation and classification, and track major trends and developments across industries.
| Market Size |
|
|
| Market Position of Top Company |
|
|
| Qualitative Analysis |
|
|
Primary Sources
As part of our primary research, we interviewed a variety of stakeholders from both the supply and demand sides to gather valuable qualitative and quantitative insights.
On the supply side, we spoke with product manufacturers, competitors, industry experts, research institutions, distributors, traders, and raw material suppliers. On the demand side, we engaged with business leaders, marketing and sales heads, technology and innovation directors, supply chain executives, and end users across key organizations.
These conversations helped us better understand market segmentation, pricing, applications, leading players, supply chains, demand trends, industry outlook, and key market dynamics—including risks, opportunities, barriers, and strategic developments.
Key Data Information from Primary Sources
| Primary Sources | Parameters | Key Data |
| Market Segments(by Application, by Type) |
|
|
| Total Market |
|
|